 | • レポートコード：MRC2203A084 • 出版社/出版日：Mordor Intelligence / 2022年3月15日 • レポート形態：英文、PDF、115ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本市場調査レポートでは、世界のカンジダ症治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、投与経路別（注射、軟膏、経口）分析、薬剤種類別（ポリエン、アゾール、エキノカンジン、その他）分析、組織種類別（口腔カンジダ症、外陰膣カンジダ症、皮膚カンジダ症、侵襲性カンジダ症、全身性カンジダ症）分析、エンドユーザー別（病院、クリニック、小売薬局、ドラッグストア）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のカンジダ症治療市場規模：投与経路別（注射、軟膏、経口） ・世界のカンジダ症治療市場規模：薬剤種類別（ポリエン、アゾール、エキノカンジン、その他） ・世界のカンジダ症治療市場規模：組織種類別（口腔カンジダ症、外陰膣カンジダ症、皮膚カンジダ症、侵襲性カンジダ症、全身性カンジダ症） ・世界のカンジダ症治療市場規模：エンドユーザー別（病院、クリニック、小売薬局、ドラッグストア） ・世界のカンジダ症治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Basilea Pharmaceuticals、Astellas、Ferrer Internacional、…） ・市場機会・将来傾向 |
The candidiasis therapeutics market is expected to witness rapid growth due to the increase in the number of patients affected by candidiasis infection, an increase in the susceptible immune-compromised patient pool, and growing awareness for candidiasis infection.
There has been an increase in the number of patients affected by candidiasis infection in the developing markets, which may boost the overall market growth over the forecast period. The Center for Disease Control and Prevention (CDC) estimates that approximately 46,000 cases of healthcare-associated invasive candidiasis occur each year, in the United States. CDC reports that the 30-day all-cause (crude) mortality among people with candidemia is approximately 30%. However, as people who develop invasive candidiasis typically have pre-medical conditions, it is generally ambiguous to determine the proportion of deaths directly attributable to the infection. This increase in the number of patients has helped in spurring the growth of the overall market. The increasing urbanization and rising hygiene awareness in developing countries may also help in the growth of the market.
Key Market Trends
Systemic Candidiasis under the Anatomy Type Segment is Anticipated to Dominate the Market during the Forecast Period
The market for systemic candidiasis is driven by the increase in the susceptible immune-compromised patient pool. Thrush occurs in approximately 2-5% of healthy newborns and affects them mainly during their first year of life. Over 1 million adult women and adolescent girls in the United States develop vaginal yeast infections each year. Therefore, the high incidence rate of candidiasis is expected to remain a major driver for the growth of the market, during the forecast period.
North America Region Holds the Largest Market Share
Due to the high investment in healthcare and awareness of diseases, the North American segment of the market studied is estimated to account for the highest market share. The candidiasis disease is growing rapidly in the United States and is not restricted to any particular region. Additionally, the North American and European regions accounted for the largest market revenue shares, due to higher awareness of the disease among individuals and the availability of better treatment. Hence, all these factors are likely to boost the market growth.
Competitive Landscape
The market studied is moderately competitive and there is a presence of local as well as international companies in te market studied. The major companies operating in the market are focusing on product innovations, expansions, finding new markets, or innovating their core competency to expand their individual market share.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Number of Patients Affected by Candidiasis Infection
4.2.2 Growing Awareness for Candidiasis Infection
4.3 Market Restraints
4.3.1 Availability of Alternative Treatments
4.3.2 Narrow Pipeline Molecules
4.3.3 Competition from Herbal Medicines and Alternate Therapies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Route of Administration
5.1.1 Injection
5.1.2 Ointment
5.1.3 Oral
5.2 By Drug Type
5.2.1 Polyene
5.2.2 Azole
5.2.3 Echinocandin
5.2.4 Other Types of Drugs
5.3 By Anatomy Type
5.3.1 Oral Candidiasis
5.3.2 Vulvovaginal Candidiasis
5.3.3 Cutaneous Candidiasis
5.3.4 Invasive Candidiasis
5.3.5 Systemic Candidiasis
5.4 By End-user
5.4.1 Hospitals
5.4.2 Clinics
5.4.3 Retail Pharmacies
5.4.4 Drug Stores
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle-East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle-East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Basilea Pharmaceuticals
6.1.2 Astellas
6.1.3 Ferrer Internacional
6.1.4 Pacgen Biopharmaceuticals
6.1.5 NovaDigm Therapeutics
6.1.6 Pevion Biotech
6.1.7 Amplyx Pharmaceuticals Inc.
6.1.8 Biomar Microbial Technologies
6.1.9 Cidara Therapeutics Inc.
6.1.10 Novabiotics Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS